Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN85429598

Enrollment

Registered

2002-02-26

Start date

2001-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia Musculoskeletal Diseases Bone density disorders

Interventions

1. Placebo once a day, at bedtime (qhs) 2. Simvastatin 20 mg qhs 3. Simvastatin 40 mg qhs

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women with osteopenia 2. Not taking oestrogen 3. Selective oestrogen receptor modulators 4. Bisphosphonates 5. Calcitonin 6. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026